This edition has totally revised chapters on drug regulation in the USA, with new contributor, Dr Peter Barton Hutt formerly FDA Special Counsel. New contributions regarding pharmaco-economics are covered in two new chapters. There are 22 chapters in all with contributions from pharmaceutical physicians, drug regulators, health economists and lawyers from UK, USA and Japan.